Aparna Hegde

5.3k total citations
31 papers, 642 citations indexed

About

Aparna Hegde is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Aparna Hegde has authored 31 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Aparna Hegde's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Aparna Hegde is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Aparna Hegde collaborates with scholars based in United States, India and Australia. Aparna Hegde's co-authors include Paul R. Walker, Cynthia R. Cherry, Nitika Sharma, Jessica Hardin, Abdul Rafeh Naqash, Teresa Parent, Alexandra Valsamakis, Jennifer A. Kanakry, Amy Greer and Allan B. Massie and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Aparna Hegde

28 papers receiving 637 citations

Peers

Countries citing papers authored by Aparna Hegde

Since Specialization

Citations

This map shows the geographic impact of Aparna Hegde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aparna Hegde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aparna Hegde more than expected).

Fields of papers citing papers by Aparna Hegde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aparna Hegde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aparna Hegde. The network helps show where Aparna Hegde may publish in the future.

Co-authorship network of co-authors of Aparna Hegde

This figure shows the co-authorship network connecting the top 25 collaborators of Aparna Hegde. A scholar is included among the top collaborators of Aparna Hegde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aparna Hegde. Aparna Hegde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma 2025 ·Cancer Immunology Research ·Larissa Anastácio da Costa Carvalho, Nataliya Tovbis Shifrin, (unknown), Michael F. Emmons, Ximo Pechuan-Jorge, (unknown), Oscar E. Ospina, (unknown), Lillian Seu, (unknown), Aparna Hegde, Nikhil I. Khushalani, Elsa Quintana, Keiran S.M. Smalley	0
2	6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) 2025 ·Journal of Thoracic Oncology ·Salman R. Punekar, (unknown), Jia Luo, S-H.I. Ou, (unknown), (unknown), Ignacio Garrido‐Laguna, (unknown), (unknown), Andreas Saltos, Priyam Mitra, Aparna Hegde, (unknown), Minoti Hiremath, Kathryn C. Arbour	1
3	Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). 2025 ·Journal of Clinical Oncology ·Ignacio Garrido‐Laguna, Brian M. Wolpin, Wungki Park, (unknown), Alexander I. Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, (unknown), Minal Barve, (unknown), (unknown), J. Randolph Hecht, (unknown), Aparna Hegde, (unknown), Tao Lin, Sumit Kar, Kevin Lin, David S. Hong	14
4	Scalable Decision-Focused Learning in Restless Multi-Armed Bandits with Application to Maternal and Child Health 2023 ·Proceedings of the AAAI Conference on Artificial Intelligence ·Kai Wang, Shresth Verma, (unknown), Sanket Shah, Aparna Taneja, (unknown), Aparna Hegde, Milind Tambe	3
5	Increasing Impact of Mobile Health Programs: SAHELI for Maternal and Child Care 2023 ·Proceedings of the AAAI Conference on Artificial Intelligence ·Shresth Verma, (unknown), (unknown), Paritosh Verma, (unknown), (unknown), Aparna Hegde, (unknown), Manish Jain, Milind Tambe, Aparna Taneja	3
6	LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801 2023 ·Annals of Oncology ·Sapna P. Patel, Megan Othus, Paul Wright, John Hyngstrom, Christopher D. Lao, (unknown), Sunandana Chandra, Kari Kendra, Craig Devoe, Aparna Hegde, Ankit Mangla, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Elad Sharon, Larissa A. Korde, James Moon, Vernon K. Sondak, Antoni Ribas, Víctor G. Prieto	7
7	Expanding impact of mobile health programs: SAHELI for maternal and child care 2023 ·AI Magazine ·Shresth Verma, (unknown), (unknown), Paritosh Verma, (unknown), (unknown), Aparna Hegde, (unknown), Manish Jain, Milind Tambe, Aparna Taneja	1
8	First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer. 2023 ·Journal of Clinical Oncology ·Daniel Morgensztern, Neal Ready, Melissa L. Johnson, Afshin Dowlati, Noura J. Choudhury, David P. Carbone, Eric Schaefer, Susanne M. Arnold, Sonam Puri, Zofia Piotrowska, Aparna Hegde, Anne C. Chiang, Wade T. Iams, Anthony W. Tolcher, Kaname Nosaki, Jiuhong Zha, Rui Li, Pooja Hingorani, Edwin E. Jeng, Muhammad Furqan	15
9	Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After 2022 ·Frontiers in Oncology ·(unknown), Aparna Hegde, Hyder Arastu, (unknown), Nitika Sharma, Paul R. Walker, (unknown)	15
10	Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes 2021 ·Aparna Hegde, (unknown)	2
11	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma 2021 ·ESMO Open ·Vivek Subbiah, Sudhakiranmayi Kuravi, Siddhartha Ganguly, Danny R. Welch, Carolyn J. Vivian, Muhammad Umair Mushtaq, Aparna Hegde, Swaminathan P. Iyer, Behrang Amini, Siraj M. Ali, Russell W. Madison, (unknown), Roy A. Jensen, Joseph P. McGuirk, Hesham M. Amin, Ramesh Balusu	10
12	Assessment of ideal serum dilution for screening of antinuclear antibodies by an indirect immunofluorescence method in diagnosis of autoimmune disorders 2020 ·Medical Journal Armed Forces India ·(unknown), Saroj Kumar Patnaik, D. S. BHAKUNI, (unknown), (unknown), (unknown), Aparna Hegde, (unknown), (unknown), (unknown)	0
13	Change in Reporting of USMLE Step 1 Scores and Potential Implications for International Medical Graduates 2020 ·JAMA ·Aakash Desai, Aparna Hegde, (unknown)	19
14	Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer 2019 ·JCO Precision Oncology ·Aparna Hegde, David S. Hong, Behrang Amini, Siraj M. Ali, (unknown), Funda Meric‐Bernstam, Vivek Subbiah	10
15	Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers 2019 ·Immunology ·Aparna Hegde, Le Huang, Shuang Liu, Kenneth R. Hess, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven Sherman, George R. Simon, George R. Blumenschein, Vassiliki A. Papadimitrakopoulou, David S. Hong, Funda Meric‐Bernstam, John V. Heymach, Vivek Subbiah	2
16	Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment? 2017 ·Bone Marrow Transplantation ·Aparna Hegde, Hemant S. Murthy	26
17	Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer. 2017 ·Journal of Clinical Oncology ·Ramya Pinnamaneni, Aparna Hegde, (unknown), Hyder Arastu, Mark Bowling, (unknown), (unknown), Cynthia R. Cherry, Paul R. Walker	5
18	Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade 2017 ·Journal of Oncology Pharmacy Practice ·(unknown), Aparna Hegde, Cynthia R. Cherry, Abdul Rafeh Naqash, Nitika Sharma, (unknown), (unknown), Teresa Parent, Jessica Hardin, Paul R. Walker	243
19	PS01.64: Effect of Anti-PD1 Therapy on the Incidence of Thromboembolic Events in Lung Cancer 2016 ·Journal of Thoracic Oncology ·Aparna Hegde, (unknown), (unknown), (unknown), Paul R. Walker	3
20	High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers 2012 ·Fertility and Sterility ·Benjamin Leader, Aparna Hegde, Quentin Baca, Kimberly Stone, (unknown), David B. Seifer, Frank J. Broekmans, Valerie L. Baker	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact